SmartCatch develops microfiltration devices that isolate circulating tumor cells (CTCs) from whole blood without pre-analytical steps, enabling real-time monitoring of cancer progression. This technology addresses the limitations of traditional tumor biopsies by providing a minimally invasive method for comprehensive cancer characterization and personalized treatment strategies.
Funding
$4.6M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Traditional tumor biopsies provide a limited snapshot of intratumoral heterogeneity, reflecting only a single point in time. Capturing and analyzing circulating tumor cells (CTCs), which are rare (1 in 1 billion blood cells) and fragile, presents a significant technical challenge.
Solution
SmartCatch develops microfiltration devices that isolate circulating tumor cells (CTCs) directly from whole blood without pre-analytical steps. This minimally invasive approach offers increased temporal and spatial representativeness of solid tumor heterogeneity, enabling real-time monitoring of disease progression and personalized treatment strategies. Their technology aims to make liquid biopsies of CTCs accessible for diagnosis, follow-up, and personalized cancer care. The company offers both benchtop instruments for research and portable systems for clinical use.
Target Audience
The primary target audience includes clinicians in medical oncology, pharmaceutical companies, and researchers seeking advanced devices for cancer diagnosis, monitoring, and personalized treatment.
Features
- Microfiltration devices for CTC isolation directly from whole blood
- No pre-analytical steps required
- CTC-Station: Benchtop instrument for studying tumor biology and accelerating drug development
- CTC-Pheresis: Portable system for prognosis and real-time treatment monitoring in clinical settings
- Facilitates multi-omic characterization of CTCs